Company Overview of Celixir Limited
Celixir Limited, a biotechnology company, discovers, develops, and delivers life-saving and life-altering regenerative medicines to help patients with the greatest medical need. Its products in pipeline include Heartcel, a investigational cardiac regenerative medicine that consists of iMP cells, which are designed to treat patients with ischaemic heart disease–ischaemic cardiomyopathy–undergoing coronary artery bypass graft; Tendoncel, an investigational topical gel that contains platelet lysate capable of regenerating injured tendons near the surface of the skin; and Myocardion progenitor cells for the treatment of patients with mild to moderate heart failure. Celixir Limited was formerly k...
The Maynard Centre
Forest Farm Industrial Estate
Cardiff, CF14 7YT
Founded in 2009
Key Executives for Celixir Limited
Founder, Chairman and Chief Scientific Officer
Co-Founder and Executive Director
Chief Medical Adviser and Research & Development Director
Compensation as of Fiscal Year 2017.
Celixir Limited Key Developments
Cell Therapy and Daiichi Sankyo Enter Licensing Agreement for Innovative Cardiac-Regenerative Treatment
May 19 16
Cell Therapy (UK) and Daiichi Sankyo (Japan) have entered into a licensing agreement in Japan for innovative cardiac-regenerative treatment Heartcel (allogeneic stem cells), the companies said in a statement. Under the agreement, Cell Therapy will receive a GBP 12.5-million upfront licensing fee and additional milestone payments and royalties, while Daiichi Sankyo will undertake all development, regulatory, and commercial activities for Heartcel in Japan. In addition, Cell Therapy will retain global rights to Heartcel outside of Japan, as well as global manufacturing responsibilities. Treatment with Heartcel involves the Heartcel product injecting modified cells into the patient's heart tissue to repair scarring associated with heart failure, a condition which affects approximately 26 million people globally.
Daiichi Sankyo Company, Limited Signs License Agreement with Cell Therapy Ltd. for Heartcel
May 10 16
Daiichi Sankyo Company, Limited announced the signing of a license agreement with Cell Therapy Ltd. for an exclusive license in Japan to develop and market Heartcel, a immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure currently in development. Heartcel is an allogeneic iMP cell therapeutic agent created using a new CTL proprietary method. Heartcel is to be injected into the cardiac muscle for expected therapeutic effects in patients suffering from ischemic heart failure. In Japan, Daiichi Sankyo will develop and market Heartcel, while CTL will maintain manufacturing responsibilities for clinical trials and commercialization. Daiichi Sankyo will make a lump-sum payment to CTL on the signing of the agreement, followed by future milestone and sales royalty payments.
Cell Therapy Limited Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016
Jan 4 16
Cell Therapy Limited Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Presentation Date & Speakers: Mar-15-2016, Ajan Reginald, Co-Founder and Executive Director, Mark Beards, Corporate Development Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|